Lattice Biologics Ltd. (TSX-V: LBL) (OTCBB: LBLTF) (“Lattice Biologics” or the “Company”) has issued common shares and warrants pursuant to a litigation settlement.
Pursuant to the litigation settlement Ms. Cheryl Farmer acquired 18,000,000 common shares of the Company representing 17.2% of the issued and outstanding common shares of the Company and 500,000 warrants of the Company. The common shares are subject to a four-month hold period. The warrants are exercisable at a price of CAD$0.10 per common share and expire on August 30, 2020.
The litigation settlement was approved by shareholders on June 29, 2020.